Hutch News

Hutch News

Stories tagged 'ASH 2018'

'Exciting' but early results in trial of immunotherapy for myeloma

Cancer cells disappeared rapidly in patients with high-risk, treatment-resistant disease

Dec. 3, 2018 | by Susan Keown / Fred Hutch News Service

The patients were out of options to treat their advanced myelomas. Then, they enrolled on a new clinical trial of genetically reprogrammed immune cells called CAR T cells.

View story >


Gene editing shows promise for sickle cell and related disorders

Preclinical results offer new hope in group of dangerous inborn diseases

May 23, 2018 | By Susan Keown / Fred Hutch News Service

New research, not yet in humans, suggests that a novel gene-editing strategy holds promise for people with sickle cell disease and other serious inborn disorders of hemoglobin.

View story >


How the immune system’s key organ regenerates itself

Watch: Hutch researcher discusses harnessing the thymus’s knack for self-repair to boost immune function and help patients

Jan. 12, 2018 | By Susan Keown (text) and Robert Hood (video) / Fred Hutch News Service

Dr. Jarrod Dudakov's discoveries about thymus regeneration could lead to new therapies to improve immune system function in old age and make immunotherapies more effective.

View story >


Promising results in trial of engineered T cells in high-risk leukemia

High response rates to experimental immunotherapy in patients with treatment-resistant chronic lymphocytic leukemia

July 17, 2017 | By Susan Keown / Fred Hutch News Service

Most patients with recurrent chronic lymphocytic leukemia who were enrolled in a small, early- phase trial saw their advanced tumors shrink or even disappear after an infusion of genetically engineered immune cells. Dr. Cameron Turtle, one of the study’s leaders, presented the results on Saturday at the 2016 annual meeting of the American Society of Hematology in San Diego.

View story >


93 percent of advanced leukemia patients in remission after immunotherapy

‘Exciting’ but early results from trial of engineered immune cells

April 25, 2016 | By Susan Keown / Fred Hutch News Service

After her immune cells were genetically engineered to target her cancer, Kristin Kleinhofer's leukemia disappeared. The trial was her and her family's 'last hope'.

View story >



(RSS feeds are best viewed in browsers other than Chrome)

Editor's Picks

GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Magazine Archive
Back issues of Hutch Magazine

Financial Reporting
Fiscal highlights & Annual Reports

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.